Determination of vascular endothelial growth factor (VEGF) in circulating blood: Significance of VEGF in various leucocytes and platelets

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 62, Issue 5, 2002, Pages 343-350

  Werther, K ^a   Christensen, I J ^a   Nielsen, H J ^a  

^a NONE   (Denmark)

Author keywords

Colorectal cancer; Granulocytes; In vitro clotting; Neutrophils; Vascular endothelial growth factor

Indexed keywords

ANTICOAGULANT AGENT; CD14 ANTIGEN; EDETIC ACID; VASCULOTROPIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CANCER STAGING; COLORECTAL CANCER; FEMALE; GRANULOCYTE; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE COUNT; VENOUS BLOOD;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; BLOOD PLATELETS; COLORECTAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; LYMPHOKINES; MALE; MIDDLE AGED; PLATELET COUNT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 0036395643     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510260296492     Document Type: Article

References (20)

1. Werther K, Christensen IJ, Brunner N, Nielsen HJ, Danish RANX. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX 05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000; 26: 657-62.
2. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002; 863: 17-23.
3. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000; 58: 169-74.
4. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Colch) 1998; 94: 395-404.
5. Scapini P, Calzetti F, Cassatella MA. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J Immunol Methods 1999; 232: 121-9.
6. Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998; 10: 254-7.
7. Bottomley MJ, Webb NJ, Watson CJ, Holt PJ, Freemont AJ, Brenchley PE. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol 1999; 117:171-6.
8. Bottomley MJ, Webb NJ, Watson CJ, Holt L, Bukhari M, Denton J, Freemont AJ, Brenchley PE. Placenta growth factor (P1GF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 2000; 119:182-8.
9. Nielsen HJ, Werther K, Mynster T, Svendsen MN, Rosendahl S, Elley T, Skov F. Bacteria-induced release of white cell-and platelet-derived vascular endothelial growth factor in vitro. Vox Sang 2001; 80: 170-8.
10. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189: 487-95.
11. Banks RE. Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998: 77: 956-64.
12. Nielsen HJ, Werther K, Mynster T, Brunner N. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 1999; 39:1078-1083
13. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5(3): 487-91.
14. Jacobsen J. Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163: 343-7.
15. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
16. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, Noguchi Y. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000; 153: 7-12.
17. Humbert JR, Fermin CD, Winsor EL. Early damage to granulocytes during storage. Semin Hematol 1991; 28 Suppl 5: 10-3.
18. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a gynecologic oncology group study. Gynecol Oncol 2000; 78: 137-42.
19. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996: 9: 1826-30.
20. Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M. Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 1995; 34: 69-73.